Literature DB >> 24847527

Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.

John H Wilton, Mark A Titus, Eleni Efstathiou, Gerald J Fetterly, James L Mohler.   

Abstract

UNLABELLED: BACKGROUND. A high throughput, high pressure liquid chromatographic (HPLC) method with triple quadrupole mass spectral detection (LC/MS/MS) was validated for the measurement of 5 endogenous androgens in human plasma and serum and applied to various in vivo and in vitro study samples to pursue a better understanding of the interrelationship of the androgen axis, intracrine metabolism, and castration-recurrent prostate cancer (CaP).
METHODS: A Shimadzu HPLC system interfaced with a Sciex QTRAP 5500 mass spectrometer with electrospray ionization was used with in line column-switching. Samples were liquid/liquid extracted and chromatographed on a Luna C18(2) column at 60°C with a biphasic gradient using a 15-min run time.
RESULTS: The method was validated for five androgens in human plasma and serum, and applied to four sets of samples. Plasma (n=188) and bone marrow aspirate (n=129) samples from patients with CaP, who received abiraterone acetate plus prednisone for up to 945 days(135 weeks), had undetectable androgens after 8 weeks of treatment. Plasma dehydroepiandrosterone(DHEA) concentrations were higher in African Americans than Caucasian Americans with newly diagnosed CaP. Analysis of prostate tumor tissue homogenates demonstrated reproducible testosterone (T) and dihydrotestosterone (DHT) concentrations with a minimal sample size of 1.0–2.0 mg of tissue. Finally, cell pellet and media samples from the LNCaP C4-2 cell line showed conversion of T to DHT.
CONCLUSION: The proposed LC/MS/MS method was validated for quantitation of five endogenous androgens in human plasma and serum, and effectively profiles androgens in clinical specimens and cell culture samples.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24847527      PMCID: PMC4335642          DOI: 10.1002/pros.22792

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  26 in total

1.  Serum testosterone levels in African-American and white men undergoing prostate biopsy.

Authors:  W S Kubricht; B J Williams; T Whatley; P Pinckard; J A Eastham
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

2.  Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.

Authors:  Christina Wang; Don H Catlin; Laurence M Demers; Borislav Starcevic; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Steroid profiles using liquid chromatography-tandem mass spectrometry with atmospheric pressure photoionization source.

Authors:  Tiedong Guo; Michael Chan; Steven J Soldin
Journal:  Arch Pathol Lab Med       Date:  2004-04       Impact factor: 5.534

4.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

Authors:  Eleni Efstathiou; Mark Titus; Dimitra Tsavachidou; Vassiliki Tzelepi; Sijin Wen; Anh Hoang; Arturo Molina; Nicole Chieffo; Lisa A Smith; Maria Karlou; Patricia Troncoso; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

5.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

6.  Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene.

Authors:  J P Deslypere; M Young; J D Wilson; M J McPhaul
Journal:  Mol Cell Endocrinol       Date:  1992-10       Impact factor: 4.102

7.  Determination of estrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MS/MS).

Authors:  M Silvia Díaz-Cruz; María J López de Alda; Ramón López; Damià Barceló
Journal:  J Mass Spectrom       Date:  2003-09       Impact factor: 1.982

8.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

9.  Racial differences in prostate androgen levels in men with clinically localized prostate cancer.

Authors:  James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

View more
  10 in total

1.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

2.  Characterization of Prostate Cancer in a Functional Eunuch.

Authors:  John J Stocking; Michael V Fiandalo; Elena A Pop; John H Wilton; Gissou Azabdaftari; James L Mohler
Journal:  J Natl Compr Canc Netw       Date:  2016-09       Impact factor: 11.908

3.  Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Authors:  Won Kim; Li Zhang; John H Wilton; Gerald Fetterly; James L Mohler; Vivian Weinberg; Allison Morse; Russell Z Szmulewitz; Terence W Friedlander; Lawrence Fong; Amy M Lin; Andrea L Harzstark; Arturo Molina; Eric J Small; Charles J Ryan
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

4.  5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.

Authors:  Diya B Joseph; Gervaise H Henry; Alicia Malewska; Jeffrey C Reese; Ryan J Mauck; Jeffrey C Gahan; Ryan C Hutchinson; James L Mohler; Claus G Roehrborn; Douglas W Strand
Journal:  J Pathol       Date:  2022-02-03       Impact factor: 7.996

5.  Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.

Authors:  Renjie Jin; Connor Forbes; Nicole L Miller; Douglas Strand; Thomas Case; Justin M Cates; Hye-Young H Kim; Phillip Wages; Ned A Porter; Krystin M Mantione; Sarah Burke; James L Mohler; Robert J Matusik
Journal:  Prostate       Date:  2022-07-12       Impact factor: 4.012

6.  NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

7.  NF-κB and androgen receptor variant expression correlate with human BPH progression.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Alex Jang; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Jay H Fowke; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2015-12-28       Impact factor: 4.104

8.  Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Authors:  Michael V Fiandalo; John H Wilton; Krystin M Mantione; Carol Wrzosek; Kristopher M Attwood; Yue Wu; James L Mohler
Journal:  Prostate       Date:  2017-12-01       Impact factor: 4.104

9.  Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS.

Authors:  Ioana Lancrajan; Regine Schneider-Stock; Elisabeth Naschberger; Vera S Schellerer; Michael Stürzl; Ralf Enz
Journal:  J Cell Mol Med       Date:  2015-03-30       Impact factor: 5.310

10.  Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

Authors:  Michael V Fiandalo; John J Stocking; Elena A Pop; John H Wilton; Krystin M Mantione; Yun Li; Kristopher M Attwood; Gissou Azabdaftari; Yue Wu; David S Watt; Elizabeth M Wilson; James L Mohler
Journal:  Oncotarget       Date:  2018-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.